MacroGenics Historical Financial Ratios
| MGNX Stock | USD 3.21 0.07 2.13% |
MacroGenics is lately reporting on over 104 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 43.87 will help investors to properly organize and evaluate MacroGenics financial condition quickly.
MacroGenics |
About MacroGenics Financial Ratios Analysis
MacroGenicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate MacroGenics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on MacroGenics financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across MacroGenics history.
MacroGenics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing MacroGenics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on MacroGenics sales, a figure that is much harder to manipulate than other MacroGenics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is MacroGenics dividend as a percentage of MacroGenics stock price. MacroGenics dividend yield is a measure of MacroGenics stock productivity, which can be interpreted as interest rate earned on an MacroGenics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from MacroGenics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into MacroGenics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.At this time, MacroGenics' PTB Ratio is fairly stable compared to the past year. Stock Based Compensation To Revenue is likely to rise to 0.33 in 2024, whereas Price To Sales Ratio is likely to drop 9.98 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.17 | 1.51 | 1.28 | 1.21 | Days Of Inventory On Hand | 604.16 | 71.72 | 54.2 | 51.49 |
MacroGenics fundamentals Correlations
Click cells to compare fundamentals
MacroGenics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MacroGenics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 8.43 | 12.26 | 12.72 | 2.71 | 10.14 | 9.98 | |
| Days Sales Outstanding | 75.0 | 86.17 | 50.12 | 135.06 | 64.41 | 43.87 | |
| Book Value Per Share | 4.8 | 5.64 | 4.0 | 2.31 | 2.46 | 2.34 | |
| Free Cash Flow Yield | (0.26) | (0.0983) | (0.16) | (0.22) | (0.13) | (0.14) | |
| Operating Cash Flow Per Share | (3.74) | (2.79) | (2.13) | (2.4) | (1.42) | (1.33) | |
| Stock Based Compensation To Revenue | 0.27 | 0.32 | 0.21 | 0.31 | 0.13 | 0.33 | |
| Capex To Depreciation | 0.4 | 0.49 | 0.55 | 0.31 | 0.18 | 0.17 | |
| Ev To Sales | 6.89 | 10.71 | 11.42 | 2.22 | 9.0 | 8.2 | |
| Free Cash Flow Per Share | (2.88) | (2.25) | (2.5) | (1.47) | (1.29) | (1.36) | |
| Roic | (0.81) | (0.4) | (0.78) | (0.83) | (1.08) | (1.13) | |
| Net Income Per Share | (4.19) | (3.16) | (2.25) | (3.18) | (1.95) | (0.15) | |
| Sales General And Administrative To Revenue | 0.21 | 0.67 | 0.74 | 0.44 | 0.39 | 0.29 | |
| Research And Ddevelopement To Revenue | 3.17 | 3.15 | 1.98 | 2.84 | 1.36 | 2.98 | |
| Capex To Revenue | 0.0692 | 0.0604 | 0.082 | 0.0238 | 0.03 | 0.0285 | |
| Cash Per Share | 4.49 | 5.2 | 4.06 | 2.51 | 3.71 | 6.94 | |
| Pocfratio | (3.9) | (10.71) | (6.69) | (4.74) | (7.62) | (8.0) | |
| Capex To Operating Cash Flow | (0.0319) | (0.0528) | (0.0431) | (0.0417) | (0.0226) | (0.0214) | |
| Pfcf Ratio | (3.78) | (10.18) | (6.41) | (4.55) | (7.45) | (7.82) | |
| Roe | (0.66) | (0.4) | (0.8) | (0.85) | (0.0594) | (0.0623) | |
| Ev To Operating Cash Flow | (3.18) | (9.36) | (6.01) | (3.89) | (6.76) | (7.1) | |
| Pe Ratio | (3.45) | (10.18) | (5.04) | (3.43) | (65.77) | (69.06) | |
| Return On Tangible Assets | (0.49) | (0.31) | (0.57) | (0.43) | (0.0295) | (0.031) | |
| Ev To Free Cash Flow | (1.68) | (3.08) | (8.89) | (5.76) | (6.61) | (6.94) | |
| Earnings Yield | (0.33) | (0.29) | (0.0982) | (0.2) | (0.0152) | (0.016) | |
| Net Debt To E B I T D A | 0.54 | 1.29 | 0.51 | 0.69 | (33.21) | (31.55) | |
| Current Ratio | 5.31 | 6.17 | 3.75 | 4.57 | 4.48 | 4.53 | |
| Tangible Book Value Per Share | 4.8 | 5.64 | 4.0 | 2.31 | 2.46 | 2.34 | |
| Receivables Turnover | 4.87 | 4.24 | 7.28 | 2.7 | 5.67 | 5.38 | |
| Graham Number | 18.46 | 16.89 | 16.92 | 10.08 | 2.85 | 2.71 | |
| Shareholders Equity Per Share | 4.8 | 5.64 | 4.0 | 2.31 | 2.46 | 2.34 | |
| Capex Per Share | 0.0892 | 0.11 | 0.1 | 0.059 | 0.0285 | 0.0271 | |
| Graham Net Net | 2.98 | 3.95 | 2.64 | 0.96 | 1.36 | 1.29 | |
| Revenue Per Share | 1.29 | 1.86 | 1.26 | 2.47 | 0.95 | 0.9 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.